Literature DB >> 11953422

A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Colleen Olive1, Michael R Batzloff, Anikó Horváth, Allan Wong, Timothy Clair, Penny Yarwood, Istvan Toth, Michael F Good.   

Abstract

The study reported here investigated the immunogenicity and protective potential of a lipid core peptide (LCP) construct containing a conserved region determinant of M protein, defined as peptide J8. Parenteral immunization of mice with LCP-J8 led to the induction of high-titer serum immunoglobulin G J8-specific antibodies when the construct was coadministered with complete Freund's adjuvant (CFA) or administered alone. LCP-J8 in CFA had significantly enhanced immunogenicity compared with the monomeric peptide J8 given in CFA. Moreover, LCP-J8/CFA and LCP-J8 antisera opsonized four different group A streptococcal (GAS) strains, and the antisera did not cross-react with human heart tissue proteins. These data indicate the potential of an LCP-based M protein conserved region GAS vaccine in the induction of broadly protective immune responses in the absence of a conventional adjuvant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953422      PMCID: PMC127950          DOI: 10.1128/IAI.70.5.2734-2738.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.

Authors:  E R Brandt; K S Sriprakash; R I Hobb; W A Hayman; W Zeng; M R Batzloff; D C Jackson; M F Good
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

2.  T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients.

Authors:  L Guilherme; S E Oshiro; K C Faé; E Cunha-Neto; G Renesto; A C Goldberg; A C Tanaka; P M Pomerantzeff; M H Kiss; C Silva; F Guzman; M E Patarroyo; S Southwood; A Sette; J Kalil
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 3.  Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity.

Authors:  J Froude; A Gibofsky; D R Buskirk; A Khanna; J B Zabriskie
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

4.  Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens.

Authors:  W Zeng; D C Jackson; J Murray; K Rose; L E Brown
Journal:  Vaccine       Date:  2000-01-06       Impact factor: 3.641

5.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

Review 6.  Streptococcal M protein: molecular design and biological behavior.

Authors:  V A Fischetti
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

7.  Induction of autoimmune valvular heart disease by recombinant streptococcal m protein.

Authors:  A Quinn; S Kosanke; V A Fischetti; S M Factor; M W Cunningham
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

8.  Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.

Authors:  D Bessen; V A Fischetti
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

9.  Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein.

Authors:  K H Wiesmüller; W Bessler; G Jung
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1983-05

10.  Multiple, heart-cross-reactive epitopes of streptococcal M proteins.

Authors:  J B Dale; E H Beachey
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  15 in total

1.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  A novel synthetic adjuvant enhances dendritic cell function.

Authors:  Karen S M Phillipps; Michelle N Wykes; Xue Q Liu; Melissa Brown; Joanne Blanchfield; Istvan Toth
Journal:  Immunology       Date:  2008-12-26       Impact factor: 7.397

4.  Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.

Authors:  Karen White; Thomas Rades; Philip Kearns; Istvan Toth; Sarah Hook
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

5.  Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins.

Authors:  Anatoly Severin; Elliott Nickbarg; Joseph Wooters; Shakey A Quazi; Yury V Matsuka; Ellen Murphy; Ioannis K Moutsatsos; Robert J Zagursky; Stephen B Olmsted
Journal:  J Bacteriol       Date:  2006-12-01       Impact factor: 3.490

6.  Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.

Authors:  Colleen Olive; Michael Batzloff; Aniko Horváth; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 7.  Cell membrane-derived nanomaterials for biomedical applications.

Authors:  Ronnie H Fang; Yao Jiang; Jean C Fang; Liangfang Zhang
Journal:  Biomaterials       Date:  2017-03-01       Impact factor: 12.479

8.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

9.  Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.

Authors:  Harry S Courtney; David L Hasty; James B Dale
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge.

Authors:  D Fischer; D Rood; R W Barrette; A Zuwallack; E Kramer; F Brown; L K Silbart
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.